AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious.

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock

AstraZeneca just wrapped up its last strategic plan successfully. It's now setting a new ambition to be completed by 2030.

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?

CAMBRIDGE, England--(BUSINESS WIRE)--Dato-DXd TL01 OS HLR.

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical sign.

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024. Presentations will include a new subgroup analyses of the Phase 3 NEURO-TTRansform study of WAINUATM (eplontersen), which was approved by the US Food and Drug Administration (FDA) in.

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?

Why Astrazeneca (AZN) is a Great Dividend Stock Right Now

Conduit Pharmaceuticals Inc

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, 2024. More than 100 abstracts will feature 25 approved and potential new medicines across the Company's diverse oncology portfolio and pipeline, including two late-breaking plenary presentations, a special late-breaking abstract session presentation and 1.

AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​

Shares in AstraZeneca PLC (LSE:AZN) were trading just off their all-time high as leading analysts provided a largely positive assessment of its growth plans, the highlight of which was a 2030 revenue target of $80 billion - a 75% increase on last year's total. There were some reservations following the drugs giant's investor day hosted by CEO Pascal Soriot, notably around its aspirations to grow the operating profit margin to 35%.

AstraZeneca: Leading banks hail Soriot's $80bn target; more detail sought

AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish drug maker announced what it called its “bold ambition” for future growth.

AstraZeneca Rises to Record High After Announcing Plans for 'New Era of Growth'

AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

After AstraZeneca PLC (LSE:AZN) unveiled new sales and profit targets for the end of the decade, analysts were mildly impressed by the ambition to "shoot for the stars". Starting with the bare numbers, UBS noted that the new target to achieve $80 billion in total revenue by 2030 compared to consensus core revenue of $67 billion and its own forecast of $72 billion.

AstraZeneca's new 2030 targets are bold attempt to reach for the stars, say analysts

Pharmaceutical company AstraZeneca is planning to increase its total revenue by 75% and release 20 new medicines by 2030, including cancer treatments.

AstraZeneca targets $80 billion in total revenue by 2030 with release of 20 new medicines

AstraZeneca on Tuesday outlined ambitions to almost double its sales over the next six years by launching 20 new medicines by 2030.

AstraZeneca kicks off ‘new era of growth' with aim to hit $80 billion of sales by 2030

AstraZeneca has set out a new revenue target as it aims to bolster its investment in technologies and platforms, and said it would develop 20 new medicines throughout the next six years.

AstraZeneca Targets $80 Billion Revenue by 2030

AstraZeneca PLC (LSE:AZN) aims to grow its revenue by about 75% to $80 billion by 2030, driven by the launch of 20 new medicines and growth in its oncology, biopharmaceuticals, and rare disease portfolios. In an announcement made ahead of the drug giant's investor day event on Tuesday, CEO Pascal Soriot, who has revitalised the company's drug pipeline over the past decade, highlighted potential blockbusters such as the lung cancer drug Tagrisso, Calquence for leukaemia, and diabetes treatment Farxiga.

AstraZeneca aims to boost revenues to $80bn by 2030

AstraZeneca laid out its target to deliver $80 billion in total revenue by 2030 on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio.

AstraZeneca aims to deliver $80 billion in total revenue by 2030

CAMBRIDGE, England--(BUSINESS WIRE)--Investor Day 2024.

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Amgen

Genmab - ADR

Novo Nordisk

Regeneron Pharmaceuticals

Bio-Techne

United Therapeutics

Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.

AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore

AstraZeneca PLC (LSE:AZN) has unveiled plans to build a US$1.5 billion (£1.2 billion) production plant in Singapore. This will be used to manufacture cancer-killing drugs known as antibody-drug conjugates, AstraZeneca announced on Monday.

AstraZeneca lays out plans for $1.5bn Singapore plant

AstraZeneca is planning to build a $1.5 billion manufacturing facility in Singapore in an effort to enhance its antibody drug conjugates (ADCs) portfolio, the drugmaker said on Monday.

AstraZeneca plans to build $1.5 bln manufacturing facility in Singapore

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen's TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to pl.

New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

Pfizer

AstraZeneca owes Pfizer $107.5 million in damages, a Delaware federal jury said on Friday after finding that AstraZeneca's blockbuster lung cancer drug Tagrisso violated its Wyeth unit's patent rights.

News for AstraZeneca Stock (AZN)